Both α-SMA expression and type-I collagen are significantly inhibited by pre-treatment with an AKT inhibitor, LY294002, in lung fibroblasts [36], and inhibitors of PI3K/AKT pathway (LY294002 and wortmannin) can reduce lung fibrosis in vivo [37]. Here, ACTA1 is linked to pulmonary fibrosis.